- Home
- CSCI vs JAGX Comparison
CSCI vs JAGX Comparison
Compare CSCI & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSCI
- JAGX
- Stock Information
- Founded
- CSCI 1990
- JAGX 2013
- Country
- CSCI Canada
- JAGX United States
- Employees
- CSCI N/A
- JAGX N/A
- Industry
- CSCI
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- CSCI
- JAGX Health Care
- Exchange
- CSCI NYSE
- JAGX Nasdaq
- Market Cap
- CSCI 11.1M
- JAGX 12.9M
- IPO Year
- CSCI 1996
- JAGX N/A
- Fundamental
- Price
- CSCI $3.00
- JAGX $0.85
- Analyst Decision
- CSCI
- JAGX
- Analyst Count
- CSCI 0
- JAGX 0
- Target Price
- CSCI N/A
- JAGX N/A
- AVG Volume (30 Days)
- CSCI 9.5K
- JAGX 542.5K
- Earning Date
- CSCI 11-12-2024
- JAGX 11-13-2024
- Dividend Yield
- CSCI N/A
- JAGX N/A
- EPS Growth
- CSCI N/A
- JAGX N/A
- EPS
- CSCI N/A
- JAGX N/A
- Revenue
- CSCI $4,834,000.00
- JAGX $10,480,000.00
- Revenue This Year
- CSCI N/A
- JAGX $18.18
- Revenue Next Year
- CSCI N/A
- JAGX $40.06
- P/E Ratio
- CSCI N/A
- JAGX N/A
- Revenue Growth
- CSCI N/A
- JAGX N/A
- 52 Week Low
- CSCI $2.50
- JAGX $0.84
- 52 Week High
- CSCI $11.10
- JAGX $21.60
- Technical
- Relative Strength Index (RSI)
- CSCI N/A
- JAGX 39.11
- Support Level
- CSCI N/A
- JAGX $0.84
- Resistance Level
- CSCI N/A
- JAGX $1.33
- Average True Range (ATR)
- CSCI 0.00
- JAGX 0.10
- MACD
- CSCI 0.00
- JAGX -0.03
- Stochastic Oscillator
- CSCI 0.00
- JAGX 1.04
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.